Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr Gong on the Importance of Molecular Profiling in mCRPC

July 15th 2024

Jun Gong, MD, discusses the importance of molecular profiling when determining optimal treatments for patients with mCRPC.

Dr Grimm on Unmet Needs After Progression to mCRPC Following ARPI Plus Chemo

July 12th 2024

Marc-Oliver Grimm, MD discusses the clinical implications, short comings, and future steps following a post-hoc analysis from the phase 3 ARASENS trial.

Tarlatamab Monotherapy Is Safe, Active in DLL3+ Neuroendocrine Prostate Cancer

July 11th 2024

A 100-mg dose of tarlatamab was safe and showed particularly robust activity in patients with DLL3-positive neuroendocrine prostate cancer.

Patient Case 1: Non-Metastatic CSPC with Rapidly Doubling PSA

July 10th 2024

Experts present a case study of a patient with non-metastatic castration-sensitive prostate cancer exhibiting rapid PSA doubling, highlighting the clinical implications and potential treatment considerations.

The Role of PSA Doubling Time in Risk Assessment

July 10th 2024

Specialists examine non-metastatic castration-sensitive prostate cancer cases, evaluating the significance of PSA doubling time and the reliability of biomarkers in risk assessment for these patients.

FDA Grants Fast Track Designation to BNT324/DB-1311 in mCRPC

July 8th 2024

The FDA has granted fast track designation to BNT324/DB-1311 for metastatic castration-resistant prostate cancer.

The Role of mTOR/Aurora A Kinase Combination Therapy Requires Further Elucidation in Solid Tumors

July 5th 2024

S. Lindsey Davis, MD, highlights data with the mTOR inhibitor sapanisertib and Aurora A kinase inhibitor alisertib in patients with solid tumors.

Dr Choudhury on Potential Future Trials Evaluating Treatment Interruption in mHSPC

July 3rd 2024

Atish D. Choudhury, MD, PhD, on the potential of future trials to investigate treatment interruption in metastatic hormone-sensitive prostate cancer.

The EMBARK trial investigating enzalutamide in NM CSPC

July 3rd 2024

Prostate cancer experts analyze the EMBARK trial, emphasizing the potential impact of an androgen receptor inhibitor in the treatment of non-metastatic castration-sensitive prostate cancer.

Evolving Treatment Paradigm and NCCN Guideline Updates

July 3rd 2024

Key opinion leaders examine the treatment landscape for castration-sensitive prostate cancer, highlighting prevalent first-line approaches and discussing the role of androgen deprivation therapy in the treatment paradigm.

FDA Grants Fast Track Designation to 225Ac-FL-020 for mCRPC

July 3rd 2024

The FDA has granted fast track designation to the radiopharmaceutical 225Ac-FL-020 for patients with metastatic castration-resistant prostate cancer.

FDA Green Lights Companion Diagnostic for Niraparib Plus Abiraterone Acetate in BRCA+ mCRPC

July 1st 2024

The FDA has approved a companion diagnostic for niraparib plus abiraterone acetate in BRCA-mutated metastatic castration-resistant prostate cancer.

Dr Gong on the Frontline Use of PARP Inhibitors in mCRPC

June 28th 2024

Jun Gong, MD, discusses the variety of PARP inhibitor–based frontline treatment regimens that are FDA approved for patients with mCRPC.

Risk Stratification and Prognostic Markers in castration-sensitive prostate cancer

June 26th 2024

The panel of prostate cancer experts explores risk stratification methodologies and prognostic markers for castration-sensitive prostate cancer, emphasizing crucial factors that influence patient categorization and treatment decisions.

Testing Principes and Benefits of Early Intervention in Castration-Sensitive Prostate Cancer

June 26th 2024

Key opinion leaders examine the principles and advantages of early intervention strategies for patients with castration-sensitive prostate cancer.

Dr Freedland on Implications of Treatment Suspension on HRQOL in High-Risk nmHSPC

June 26th 2024

Stephen J. Freedland, MD, discusses the effects of treatment suspension on HRQOL in nonmetastatic hormone-sensitive prostate cancer in the EMBARK trial.

Dr Kyriakopoulos on Adding Cabazitaxel to Abiraterone/Prednisone in Patients With MCRPC

June 25th 2024

Christos Kyriakopoulos, MD discusses adding cabazitaxel to abiraterone/prednisone in patients with metastatic castration-resistant prostate cancer.

ARASENS Trial Demonstrates Significant Survival Benefits With Triplet Therapy in mHSPC

June 25th 2024

Darolutamide plus ADT and docetaxel showed improved outcomes in patients with metastatic hormone-sensitive prostate cancer.

Dr Grimm on Post-Progression OS After Darolutamide Plus ADT/Docetaxel in mHSPC

June 21st 2024

Marc-Oliver Grimm, MD discusses darolutamide in combination with androgen deprivation therapy and docetaxel in mHSPC.

Dr Choudhury on the Evaluation of Treatment Interruption After Response in mHSPC

June 17th 2024

Atish D. Choudhury, MD, PhD, on a phase 2 trial evaluating ADT interruption in metastatic hormone-sensitive prostate cancer after AR inhibitor response.